STEM-PD reported first human data supporting the feasibility and safety of an off-the-shelf stem cell approach for Parkinson’s disease. In the Phase 1/2 open-label trial, eight participants in Lund, Sweden received cryopreserved, human pluripotent stem cell–derived dopaminergic progenitor cells. The trial’s reported early outcomes add to growing evidence that cell-replacement strategies can be delivered safely using scalable manufacturing formats. The study was published in Nature Medicine, marking a notable milestone for translational timing as the field works to demonstrate clinical signal beyond target engagement. Together with related ISSCR 2026 updates, the STEM-PD results keep attention on next-generation dopaminergic progenitors as candidates for disease-modifying goals.